EUCTR2006-002468-24-LV进行中（未招募）1 期
A double-blind, randomized, stratified, multi-center trial evaluating conventional and double dose oseltamivir in the treatment of immunocompromised patients with influenza
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 205
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age greater than or equal to 1 year
- •Rapid diagnostic test, PCR, or viral culture positive for influenza
- •Immunocompromised subject defined as one who meets any of the following:
- •- Primary immunodeficiency at risk for viral infections OR
- •- Secondary immunodeficiency
- •- SOT with ongoing immunosuppression OR
- •- Allogenic HSCT with ongoing immunosuppression
- •- HIV with CD4 count < 500/mm3 and, in the investigator’s opinion, considered immunocompromised OR
- •- Hematologic malignancies OR
- •- Systemic (e.g. enteric, sc, im or iv)
- •immunosuppressive therapy, irrespective of medical indication, started at least 12 weeks prior to, and ongoing at the time of first dose of study drug
- •Symptoms suggestive of influenza like illness including, but not limited to fever, cough, or coryza
- •Use of an effective contraceptive, as specified by protocol; women of childbearing potential cannot be pregnant or breastfeeding.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 19
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 168
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •Influenza vaccination with live attenuated vaccine in the 2 weeks prior to randomization
- •Antiviral treatment for influenza in 2 weeks prior to randomization
- •Severe hepatic impairment
- •Any current renal replacement therapy
- •Any gastrointestinal disorders which may intefere with the absorption of Tamiflu
- •Participation in a study with an investigational drug from 4 weeks prior to study start until study end
研究者
相似试验
进行中（未招募）
1 期
A clinical trial testing usual dose and double dose oseltamivir (the medicine) in which neither the doctor or patient know what dose of medicine is given for treatment of influenza (the flu), in patients with a weakened immune (protective) system.To investigate the optimal therapy for influenza in immunocompromised patients.MedDRA version: 17.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2006-002468-24-HUF.Hoffmann-La Roche Ltd.166
进行中（未招募）
1 期
A clinical trial testing usual dose and double dose oseltamivir (the medicine) in which neither the doctor or patient know what dose of medicine is given for treatment of influenza (the flu), in patients with a weakened immune (protective) system.EUCTR2006-002468-24-BGF.Hoffmann-La Roche Ltd.228
进行中（未招募）
1 期
A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenzaimmunocompromised transplant recipients.MedDRA version: 8.1Level: LLTClassification code 10022000Term: InfluenzaEUCTR2006-002468-24-FRF.Hoffmann-La Roche Ltd.250
进行中（未招募）
1 期
A clinical trial testing usual dose and double dose oseltamivir (the medicine) in which neither the doctor or patient know what dose of medicine is given for treatment of influenza (the flu), in patients with a weakened immune (protective) system.To investigate the optimal therapy for influenza in immunocompromised patients.MedDRA version: 18.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2006-002468-24-LTF.Hoffmann-La Roche Ltd.205
进行中（未招募）
1 期
A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenzaTo investigate the optimal therapy for influenza in immunocompromised transplant recipients.MedDRA version: 8.1 Level: LLT Classification code 10022000 Term: InfluenzaEUCTR2006-002468-24-GBF.Hoffmann-La Roche Ltd.215